Visit to FDA Office of Generic Drugs
Drs. Byron, Longest and Hindle were recently invited to visit the Office of Generic Drugs at FDA to give presentations about their FDA funded research.
Our visit was hosted by VCU alum, Dr. Renish Delvadia, who arranged lunch with the growing number of VCU School of Pharmacy and School of Engineering alumni who are now working at FDA. It was great to catch up with so many former students and post-docs, who have gone on to successful careers in the regulatory world.
Listed below are the titles of the presentations
Computational fluid dynamic (CFD) models for prediction of regional drug deposition from orally inhaled drug products- Dr. Worth Longest
Clinically relevant in vitro performance tests for assessment of orally inhaled and nasal drug products– Dr. Peter Byron
Clinically relevant in vitro performance tests for assessment of orally inhaled and nasal drug products – Dr. Michael Hindle
CFD models for prediction of regional drug deposition from nasal drug products – Dr. Worth Longest
Future considerations for CFD and clinically relevant in vitro methods for orally inhaled and nasal drug products: Drs. Byron, Hindle and Longest
Details about some of our research can be found at the link below.
Source: Generic Drug User Fee Amendments of 2012 > Locally-Acting Orally-Inhaled and Nasal Drug Products